379 related articles for article (PubMed ID: 25175600)
61. Ligand binding and antigenic properties of a human neonatal Fc receptor with mutation of two unpaired cysteine residues.
Andersen JT; Justesen S; Fleckenstein B; Michaelsen TE; Berntzen G; Kenanova VE; Daba MB; Lauvrak V; Buus S; Sandlie I
FEBS J; 2008 Aug; 275(16):4097-110. PubMed ID: 18637944
[TBL] [Abstract][Full Text] [Related]
62. Influence of FcRn binding properties on the gastrointestinal absorption and exposure profile of Fc molecules.
Lawrence SA; Blankenship R; Brown R; Estwick S; Ellis B; Thangaraju A; Datta-Mannan A
Bioorg Med Chem; 2021 Feb; 32():115942. PubMed ID: 33461147
[TBL] [Abstract][Full Text] [Related]
63. In Translation: FcRn across the Therapeutic Spectrum.
Qi T; Cao Y
Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33802650
[TBL] [Abstract][Full Text] [Related]
64. Monomeric IgG1 Fc molecules displaying unique Fc receptor interactions that are exploitable to treat inflammation-mediated diseases.
Ying T; Feng Y; Wang Y; Chen W; Dimitrov DS
MAbs; 2014; 6(5):1201-10. PubMed ID: 25517305
[TBL] [Abstract][Full Text] [Related]
65. Identification of IgG(1) variants with increased affinity to FcγRIIIa and unaltered affinity to FcγRI and FcRn: comparison of soluble receptor-based and cell-based binding assays.
Lu Y; Vernes JM; Chiang N; Ou Q; Ding J; Adams C; Hong K; Truong BT; Ng D; Shen A; Nakamura G; Gong Q; Presta LG; Beresini M; Kelley B; Lowman H; Wong WL; Meng YG
J Immunol Methods; 2011 Feb; 365(1-2):132-41. PubMed ID: 21185301
[TBL] [Abstract][Full Text] [Related]
66. Sedimentation equilibrium analysis of recombinant mouse FcRn with murine IgG1.
Schuck P; Radu CG; Ward ES
Mol Immunol; 1999; 36(15-16):1117-25. PubMed ID: 10698313
[TBL] [Abstract][Full Text] [Related]
67. A strategy for bacterial production of a soluble functional human neonatal Fc receptor.
Andersen JT; Justesen S; Berntzen G; Michaelsen TE; Lauvrak V; Fleckenstein B; Buus S; Sandlie I
J Immunol Methods; 2008 Feb; 331(1-2):39-49. PubMed ID: 18155020
[TBL] [Abstract][Full Text] [Related]
68. Fc Engineering: Tailored Synthetic Human IgG1-Fc Repertoire for High-Affinity Interaction with FcRn at pH 6.0.
Saxena A; Bai B; Hou SC; Jiang L; Ying T; Miersch S; Sidhu SS; Wu D
Methods Mol Biol; 2018; 1827():399-417. PubMed ID: 30196509
[TBL] [Abstract][Full Text] [Related]
69. Effects of receptor dimerization on the interaction between the class I major histocompatibility complex-related Fc receptor and IgG.
Raghavan M; Wang Y; Bjorkman PJ
Proc Natl Acad Sci U S A; 1995 Nov; 92(24):11200-4. PubMed ID: 7479965
[TBL] [Abstract][Full Text] [Related]
70. The X-Ray Crystallographic Structure of the Human Neonatal Fc Receptor at Acidic pH Gives Insights into pH-Dependent Conformational Changes.
Taha M; Ward SE; Nam HJ
Protein Pept Lett; 2016; 23(6):525-9. PubMed ID: 27041699
[TBL] [Abstract][Full Text] [Related]
71. Crystal structure of an HSA/FcRn complex reveals recycling by competitive mimicry of HSA ligands at a pH-dependent hydrophobic interface.
Schmidt MM; Townson SA; Andreucci AJ; King BM; Schirmer EB; Murillo AJ; Dombrowski C; Tisdale AW; Lowden PA; Masci AL; Kovalchin JT; Erbe DV; Wittrup KD; Furfine ES; Barnes TM
Structure; 2013 Nov; 21(11):1966-78. PubMed ID: 24120761
[TBL] [Abstract][Full Text] [Related]
72. Human serum albumin presents isoform variants with altered neonatal Fc receptor interactions.
Leblanc Y; Berger M; Seifert A; Bihoreau N; Chevreux G
Protein Sci; 2019 Nov; 28(11):1982-1992. PubMed ID: 31583777
[TBL] [Abstract][Full Text] [Related]
73. Mapping the site on human IgG for binding of the MHC class I-related receptor, FcRn.
Kim JK; Firan M; Radu CG; Kim CH; Ghetie V; Ward ES
Eur J Immunol; 1999 Sep; 29(9):2819-25. PubMed ID: 10508256
[TBL] [Abstract][Full Text] [Related]
74. Structural characterization of a human Fc fragment engineered for extended serum half-life.
Oganesyan V; Damschroder MM; Woods RM; Cook KE; Wu H; Dall'acqua WF
Mol Immunol; 2009 May; 46(8-9):1750-5. PubMed ID: 19250681
[TBL] [Abstract][Full Text] [Related]
75. Dissection of the neonatal Fc receptor (FcRn)-albumin interface using mutagenesis and anti-FcRn albumin-blocking antibodies.
Sand KM; Dalhus B; Christianson GJ; Bern M; Foss S; Cameron J; Sleep D; Bjørås M; Roopenian DC; Sandlie I; Andersen JT
J Biol Chem; 2014 Jun; 289(24):17228-39. PubMed ID: 24764301
[TBL] [Abstract][Full Text] [Related]
76. Crystallization and stoichiometry of binding of a complex between a rat intestinal Fc receptor and Fc.
Huber AH; Kelley RF; Gastinel LN; Bjorkman PJ
J Mol Biol; 1993 Apr; 230(3):1077-83. PubMed ID: 8478919
[TBL] [Abstract][Full Text] [Related]
77. Engineered human IgG antibodies with longer serum half-lives in primates.
Hinton PR; Johlfs MG; Xiong JM; Hanestad K; Ong KC; Bullock C; Keller S; Tang MT; Tso JY; Vásquez M; Tsurushita N
J Biol Chem; 2004 Feb; 279(8):6213-6. PubMed ID: 14699147
[TBL] [Abstract][Full Text] [Related]
78. Impact of SPR biosensor assay configuration on antibody: Neonatal Fc receptor binding data.
Wang X; McKay P; Yee LT; Dutina G; Hass PE; Nijem I; Allison D; Cowan KJ; Lin K; Quarmby V; Yang J
MAbs; 2017; 9(2):319-332. PubMed ID: 28001487
[TBL] [Abstract][Full Text] [Related]
79. Identification of critical IgG binding epitopes on the neonatal Fc receptor.
Vaughn DE; Milburn CM; Penny DM; Martin WL; Johnson JL; Bjorkman PJ
J Mol Biol; 1997 Dec; 274(4):597-607. PubMed ID: 9417938
[TBL] [Abstract][Full Text] [Related]
80. Evaluation of an FcRn affinity chromatographic method for IgG1-type antibodies and evaluation of IgG variants.
Cymer F; Schlothauer T; Knaupp A; Beck H
Bioanalysis; 2017 Sep; 9(17):1305-1317. PubMed ID: 28901177
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
